AI system to predict response to Atezolizumab-Bevacizumab in unresectable liver cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a multicenter retrospective study led by the First Affiliated Hospital of Wenzhou Medical University that will collect data from about 400 patients treated with atezolizumab-bevacizumab between 2020 and 2025. The goal is to develop a non-invasive AI model using pre-treatment imaging and clinical data to forecast treatment response and outcomes. No experimental treatment will be given; the study analyzes existing records to identify predictive patterns. The study will include patients with adequate imaging and laboratory data and exclude those with missing data or significant comorbidities that hinder evaluation. Results could help tailor therapy choices for patients with unresectable HCC.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* (i) Clinical or pathological diagnosis of HCC;
* (ii) Administration of atezolizumab-bevacizumab treatment;
* (iii) At least 18 years old.

Exclusion Criteria:

* (i) Lack of key clinical data (laboratory test results), or lack of enhanced CT images taken within one month before treatment;
* (ii) Comorbid with other malignant tumors;
* (iii) PS score \> 2 or Child-Pugh score \> 7;
* (iv) Unable to evaluate tumor response;
* (v) Loss to follow-up.

Where it's running

• First Affiliated Hospital of Wenzhou Medical University
  Wenzhou, Zhejiang, China Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Bevacizumab followed by atezolizumab versus both together for advanced hepatocellular carcinoma with MASLD

  This test will see if giving bevacizumab first and then atezolizumab works better than giving both at the same time for adults with advanced hepatocellular carcinoma and metabolic-associated steatotic liver disease (MASLD).

  Recruiting Phase 2/3 Eastern Hepatobiliary Surgery Hospital · Shanghai, Shanghai Municipality · NCT07285850

• Fecal microbiota transfer to overcome resistance to atezolizumab/bevacizumab in liver cancer

  This will test whether adding fecal microbiota transfer to standard atezolizumab/bevacizumab helps adults with advanced hepatocellular carcinoma respond better.

  Recruiting Phase 2 University Hospital Heidelberg · Heidelberg, Baden-Wurttemberg and 6 other locations · NCT05690048

• Blood biomarkers to predict response to atezolizumab plus bevacizumab in hepatocellular carcinoma

  This study tests whether blood-based biomarkers can predict which patients with advanced liver cancer will respond to first-line atezolizumab plus bevacizumab.

  Recruiting Shanghai Zhongshan Hospital · Shanghai, Shanghai Municipality · NCT07734857

• Combining two immunotherapies, a bevacizumab biosimilar, and liver-artery chemotherapy to shrink advanced liver cancer for possible surgery

  This treatment will try a combo of two immune drugs (sintilimab and ipilimumab N01), a bevacizumab biosimilar, and hepatic arterial infusion chemotherapy to shrink unresectable intermediate-to-advanced hepatocellular carcinoma so more patients can become eligible for surgery.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT07560488

• TIPS benefits for people with hepatocellular carcinoma taking Tecentriq (atezolizumab) plus Avastin (bevacizumab) as first-line therapy.

  This study will try to see if placing a TIPS device helps people with advanced or unresectable hepatocellular carcinoma who are starting first-line treatment with Tecentriq plus Avastin.

  Recruiting Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Düsseldorf, North Rhine-Westphalia · NCT07365930

• Using fecal microbiota transplantation to try to restore response to atezolizumab and bevacizumab in people with unresectable hepatocellular carcinoma.

  This will try whether giving a fecal microbiota transplant and then restarting atezolizumab plus bevacizumab can restore treatment response in adults with unresectable HCC who progressed early on those drugs.

  Recruiting Phase 2 IRCCS Azienda Ospedaliero-Universitaria di Bologna · Bologna, BO · NCT07276100

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.